Matthew Gall - Iteos Therapeutics Chief Officer
| ITOS Stock | USD 6.83 0.06 0.87% |
Insider
Matthew Gall is Chief Officer of Iteos Therapeutics
| Age | 48 |
| Address | 321 Arsenal Street, Watertown, MA, United States, 02472 |
| Phone | 339 217 0161 |
| Web | https://www.iteostherapeutics.com |
Matthew Gall Latest Insider Activity
Tracking and analyzing the buying and selling activities of Matthew Gall against Iteos Therapeutics stock is an integral part of due diligence when investing in Iteos Therapeutics. Matthew Gall insider activity provides valuable insight into whether Iteos Therapeutics is net buyers or sellers over its current business cycle. Note, Iteos Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Iteos Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Matthew Gall few days ago Acquisition by Matthew Gall of 145000 shares of Iteos Therapeutics at 7.05 subject to Rule 16b-3 | ||
Matthew Gall over three months ago Acquisition by Matthew Gall of 5000 shares of Iteos Therapeutics at 7.727 subject to Rule 16b-3 |
Iteos Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1447) % which means that it has lost $0.1447 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2307) %, meaning that it created substantial loss on money invested by shareholders. Iteos Therapeutics' management efficiency ratios could be used to measure how well Iteos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.21 in 2025. Return On Capital Employed is likely to drop to -0.26 in 2025. At this time, Iteos Therapeutics' Net Tangible Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 186.3 M in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 4.1 M in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| Nur Nicholson | Apellis Pharmaceuticals | 54 | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Walter Reiher | Revolution Medicines | N/A | |
| Bruce CFA | Kymera Therapeutics | N/A | |
| Lisa TesvichBonora | Erasca Inc | N/A | |
| Jenna Cohen | Blueprint Medicines Corp | N/A | |
| Ted Yednock | Annexon | 67 | |
| John Castle | Monte Rosa Therapeutics | 54 | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| Ray Lockard | Tscan Therapeutics | N/A | |
| Siew MS | Acumen Pharmaceuticals | N/A | |
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
| Sharon Townson | Monte Rosa Therapeutics | 50 | |
| Jonathan MD | Erasca Inc | 53 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Oliver Daltrop | MoonLake Immunotherapeutics | N/A | |
| Michael Todisco | Kymera Therapeutics | 59 | |
| Sean Jeffries | Design Therapeutics | 45 | |
| Nello MD | Kymera Therapeutics | 46 | |
| JD MBA | Monte Rosa Therapeutics | 46 | |
Management Performance
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.14 |
Iteos Therapeutics Leadership Team
Elected by the shareholders, the Iteos Therapeutics' board of directors comprises two types of representatives: Iteos Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Iteos. The board's role is to monitor Iteos Therapeutics' management team and ensure that shareholders' interests are well served. Iteos Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Iteos Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Gall, Chief Officer | ||
| Matthew MBA, Chief Officer | ||
| Ryan Baker, Head Relations | ||
| Phillipe Brantegem, VicePresident Resources | ||
| Joanne MD, Chief Officer | ||
| Adi Osovsky, Executive Legal | ||
| Michel Detheux, CEO President | ||
| Yvonne McGrath, Chief Officer | ||
| FACP MD, Interim Officer | ||
| David MD, Chief Officer | ||
| Philippe Brantegem, Executive Resources |
Iteos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Iteos Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.14 | ||||
| Operating Margin | (4.48) % | ||||
| Current Valuation | (223.72 M) | ||||
| Shares Outstanding | 38.19 M | ||||
| Shares Owned By Insiders | 1.10 % | ||||
| Shares Owned By Institutions | 91.18 % | ||||
| Number Of Shares Shorted | 1.58 M | ||||
| Price To Earning | 50.50 X | ||||
| Price To Book | 0.45 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.